Navigation Links
Watson Launches Generic FEMCON(R) Fe
Date:9/26/2011

PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today. FEMCON(R) Fe is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

For the most recent twelve months ending July 31, 2011, FEMCON(R) Fe had sales of approximately $35 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third part
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
2. Watson to Present at the Jefferies 2011 Global Healthcare Conference
3. Watson Confirms Amphastar Patent Lawsuit
4. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
5. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
6. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
7. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
8. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
9. Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
10. Watson Confirms JALYN™ Patent Challenge
11. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
(Date:3/27/2015)... --  Hospira, Inc. (NYSE: HSP ), ... leading provider of injectable drugs and infusion technologies, ... biosimilarity of its proposed biosimilar, Epoetin Hospira, with ... approved name of RETACRIT™, compared to the reference ... were presented at the National Kidney Foundation (NKF) ...
(Date:3/27/2015)... -- Johnson & Johnson (NYSE: JNJ ) will webcast its ... Thursday, April 23, 2015, from the State Theatre in ... other interested parties may access the live audio webcast of ... and clicking on the webcast icon. A ... a few hours after the live meeting concludes.  The webcast ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... LOUIS, March 1, 2011 K-V Pharmaceutical Company (NYSE: KVa/KVb) ... million of senior secured notes due 2015 (the "Notes") in ... The Notes will be offered only to accredited investors pursuant ... amended (the "Securities Act").  The Notes have not been registered ...
... Medical Systems Ltd. (Nasdaq: DHRM ) ... the development, assembly, marketing and sale of medical ... announced that management will present at the following ... http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) Rodman & Renshaw ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 2K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 3K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 4K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 5K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 6K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 7K-V Pharmaceutical Company Announces $200 Million Private Debt Offering 8Dehaier Medical Announces March Investor Presentations 2
(Date:3/28/2015)... (PRWEB) March 28, 2015 Early surgery ... with Type V AC joint injuries, according to new ... today at the American Orthopaedic Society for Sports Medicine’s ... to duty faster when surgery was not performed. , ... 7 receiving surgical treatment and 17 receiving non-surgical therapy. ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... from dating experts Samantha Sanderson and Jason Rogers has ... buzz of media attention. The commotion surrounding the course's ... prompting him to publish an in-depth review of the ... when the men in their lives suddenly start pulling ...
(Date:3/27/2015)... York, New York (PRWEB) March 27, 2015 ... ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin medication increases ... diabetes has granted Pfizer Inc.’s Motion to Dismiss four ... According to a Case Management Order issued in the ... 23rd, the Court determined that the dismissals were warranted ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... increased 48% over 2006 to $701 million, SAN ... ) today reported financial results for the quarter and,year ... of $222.0,million for the quarter ended December 31, 2007, ... was $76.9 million, or $0.57 per share for,the quarter ...
... Launch Vitals.com Which Offers Free Comprehensive Doctor ... Information and Reviews, ... one of the,nation,s top 10 public relations firms, today announced the ... execute a,comprehensive communications program for the free, online doctor evaluation,service., ...
... with chronic hepatitis C (HCV) infection should not ... published in Clinical Gastroenterology and Hepatology , ... (AGA) Institute. Researchers found that HCV patients who ... of moderate to severe liver fibrosis, or tissue ...
... need of support, THOUSAND OAKS, Calif., Jan. ... experience for women with only a fading,reference to ... Mental,Health Association, in the first three months after ... or exhibit negative,behavior toward their infant. Mothers experiencing ...
... The more scientists learn about microRNAs short strands ... the more obvious it becomes how closely they ... at The Wistar Institute and their colleagues have identified ... metastasis. One of the miRNAs may provide an early ...
... Psychological interventions for cancer patients do more than just ... research suggests. , A study of 227 breast cancer ... intervention program were rated as having better health by ... started. , One particularly important result was that patients ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2007 Financial Results 7Health News:MWW Group Selected by First-Ever Online Doctor Evaluation Service Vitals.com 2Health News:Regular marijuana use increases risk of hepatitis C-related liver damage 2Health News:Regular marijuana use increases risk of hepatitis C-related liver damage 3Health News:Blue Cross of California Launches Maternity Depression Program 2Health News:Blue Cross of California Launches Maternity Depression Program 3Health News:2 microRNAs promote spread of tumor cells 2Health News:2 microRNAs promote spread of tumor cells 3Health News:Intervention program boosts health, reduces symptoms in breast cancer patients 2Health News:Intervention program boosts health, reduces symptoms in breast cancer patients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: